(Q36413164)

14 August 2017

1 reference

title

Lysosomal storage diseases: natural history and ethical and economic aspects (English)

1 reference

14 August 2017

0 references

1 reference

Ernest Beutler

1

1 reference

14 August 2017

publication date

3 March 2006

1 reference

Molecular Genetics and Metabolism

14 August 2017

published in

1 reference

14 August 2017

volume

88

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

208-215

1 reference

Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Treatment of Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Treatment of Gaucher's disease with liposome-entrapped glucocerebroside: beta-glucosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Gaucher disease as a paradigm of current issues regarding single gene mutations of humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Treatment regimens in Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Enzyme replacement therapy for Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Enzyme replacement with red cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

The clinical course of treated and untreated Gaucher disease. A study of 45 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Withdrawal of enzyme replacement therapy in Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Enzyme Augmentation in Moderate to Life-Threatening Gaucher Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

A less costly regimen of alglucerase to treat Gaucher's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Cessation of enzyme replacement therapy in Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Individualised low-dose alglucerase therapy for type 1 Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Engineering the economic value of two pediatric combination vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Ethics in practice: managed care and the changing health care environment: medicine as a profession managed care ethics working group statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

The case for a new national program for the development of cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

Replacement therapy with imiglucerase for type 1 Gaucher's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.01.010

10.1016/J.YMGME.2006.01.010

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference